Long-term, open-label study of the safety and efficacy of atomoxetine in adults with attention-deficit/hyperactivity disorder: An interim analysis

Journal of Clinical Psychiatry

Volumn 66, Issue 3, 2005, Pages 294-299

  Adler, Lenard A ^a   Spencer, Thomas J ^b   Milton, Denái R ^c   Moore, Rodney J ^c   Michelson, David ^c,d  

^a NEW YORK UNIVERSITY   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c Lilly Research Laboratory   (United States)

^d ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATOMOXETINE; PLACEBO;

ADULT; AGED; ANALYTIC METHOD; ANXIETY; APPETITE DISORDER; ARTHRALGIA; ARTICLE; ATTENTION DEFICIT DISORDER; BACKACHE; BLOOD PRESSURE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; ERECTILE DYSFUNCTION; FATIGUE; FEMALE; HEADACHE; HEART RATE; HUMAN; INSOMNIA; INTERIM ANALYSIS; IRRITABILITY; LIBIDO DISORDER; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; NAUSEA; OUTCOMES RESEARCH; PHARYNGITIS; POPULATION RESEARCH; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RHINOPHARYNGITIS; SCREENING; SIDE EFFECT; SINUSITIS; UPPER RESPIRATORY TRACT INFECTION; URINARY HESITANCY; WEIGHT REDUCTION; XEROSTOMIA;

EID: 16444366265     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v66n0304     Document Type: Article

References (26)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Washington, DC: American Psychiatric Press; 2000
2. Barkley RA. Attention-Deficit Hyperactivity Disorder: A Handbook for Diagnosis and Treatment. 2nd ed. New York, NY: Guilford Press; 1998
3. Goldman LS, Genel M, Bezman RJ, et al, for the Council on Scientific Affairs, American Medical Association. Diagnosis and treatment of attention-deficit/hyperactivity disorder in children and adolescents. JAMA 1998;279:1100-1107
4. Wender PH. Attention-deficit hyperactivity disorder in adults. Psychiatr Clin North Am 2000;21:761-774
5. Seidman LJ, Biederman J, Weber W, et al. Neuropsychological function in adults with attention-deficit hyperactivity disorder. Biol Psychiatry 1998;44:260-268
6. Barkley RA, Guevremont DC, Anastopoulos AD, et al. Driving-related risks and outcomes of attention deficit hyperactivity disorder in adolescents and young adults: a 3- to 5-year follow-up survey. Pediatrics 1993;92:212-218
7. Biederman J, Spencer T. Attention-deficit/hyperactivity disorder (ADHD) as a noradrenergic disorder. Biol Psychiatry 1999;46:1234-1242
8. Faraone SV, Biederman J. Neurobiology of attention-deficit hyperactivity disorder. Biol Psychiatry 1998;44:951-958
9. Wilens TE. The stimulants revisited. Child Adolesc Psychiatr Clin N Am 2000;9:573-603
10. Wilens TE, Biederman J, Prince J, et al. Six-week, double-blind, placebo-controlled study of desipramine for adult attention deficit hyperactivity disorder. Am J Psychiatry 1996;153:1147-1153
11. Wilens TE, Spencer TJ, Biederman J, et al. A controlled clinical trial of bupropion for attention deficit hyperactivity disorder in adults. Am J Psychiatry 2001;158:282-288
12. Wender PH, Reimherr FW. Bupropion treatment of attention-deficit hyperactivity disorder in adults. Am J Psychiatry 1990;147:1018-1020
13. Michelson D, Gao H, Allen AJ, et al. Plasma atomoxetine concentration and response to ADHD in children and adolescents [poster]. Presented at the 42nd annual meeting of the New Clinical Drug Evaluation Unit; June 10-13, 2002; Boca Raton, Fla. Poster II-3
14. Michelson D, Faries D, Wernicke J, et al. Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics 2001;108:E83
15. Spencer T, Heiligenstein JH, Biederman J, et al. Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder. J Clin Psychiatry 2002;63:1140-1147
16. Michelson D, Allen AJ, Busner J, et al. Once-daily atomoxetine treatment for children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatry 2002;159:1896-1901
17. Spencer T, Biederman J, Wilens T, et al. Effectiveness and tolerability of tomoxetine in adults with attention deficit hyperactivity disorder. Am J Psychiatry 1998;155:693-695
18. Michelson D, Adler L, Spencer T, et al. Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. Biol Psychiatry 2003;53:112-120
19. Adler LA, Chua HC. Management of ADHD in adults. J Clin Psychiatry 2002;63(suppl 12):29-35
20. Conners CK, Erhardt D, Sparrow E. Conners' Adult ADHD Rating Scales (CAARS). North Tonawanda, NY: Multi-Health Systems Inc; 1999
21. Guy W. ECDEU Assessment Manual for Psychopharmacology, Revised. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, Md: National Institute of Mental Health; 1976
22. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967;6:278-296
23. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62
24. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol 1959;32:50-55
25. Wender PH, Reimherr FW, Wood D, et al. A controlled study of methyl-phenidate in the treatment of attention deficit disorder, residual type, in adults. Am J Psychiatry 1985;142:547-552
26. Leon AC, Olfson M, Portera L, et al. Assessing psychiatric impairment in primary care with the Sheehan Disability Scale, Int J Psychiatry Med 1997;27:93-105